Flacco ME, et al. - Researchers undertook a systematic review and meta-analysis to provide quantitative estimates for the immunogenicity, persistence of immunogenicity, and safety of 4CMenB in children and adolescents. In this work, 4CMenB was found to have an acceptable short-term safety profile. The primary course is sufficient to achieve a satisfactory immune response within 30 days of vaccination. Among children, a need for a booster dose was observed for achieving prolonged protection against strain M10713. The long-term immunogenicity against strain NZ98/254 remained suboptimal.